%PDF-1.5
%
2 0 obj
<<
/Lang (en-US)
/MarkInfo <<
/Marked true
>>
/Metadata 4 0 R
/Pages 5 0 R
/StructTreeRoot 6 0 R
/Type /Catalog
>>
endobj
4 0 obj
<<
/Length 6073
/Subtype /XML
/Type /Metadata
>>
stream
application/pdf
Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients
Muhammed Furkan Ercisli1
Gao Lechun2
Sarhang Hasan Azeez 3
Rebwar Muhammad Hamasalih4
Siyan Song5
Zahra Aziziaram6*
Rivaroxaban is an anticoagulant drug that prevents forming of blood clots. In addition, it can be administered to prevent and treat thrombotic diseases such as atrial fibrillation, cardiac arrhythmia, heart valve disease, orthopedic surgery, and thrombophilia to reduce the risk of thrombosis. Various factors such as age, gender, diet, medications, and genetic factors effectively determine the dose of rivaroxaban. Genetic variability in drug-metabolizing enzymes, including the cytochrome P450 (CYP450) enzymes and especially CYP3A4, has been associated with rivaroxaban response. The current study aimed to identify the frequency of CYP3A4 common polymorphisms, as well as their association with rivaroxaban response in 100 patients of Arab descent (48.6% female). CYP3A4 gene polymorphisms were examined by the PCR-RFLP method, and the findings were analyzed by SPSS 16 software and t-test. The frequency of CYP3A4*1B/*1B, CYP3A4*1B/*1A, CYP3A4*1B/*1C, and CYP3A4*1A/*1C was 67.35%, 10.64%, 19.12% and 2.89%, respectively. According to our results, CYP3A4 *1B/*1B genotype was the most common, and patients with CYP3A4*1B/*1B alleles needed a higher daily dose of rivaroxaban than *1B/*1A, *1B/*1C, and *1A/*1C carriers (9.57 ± 1.54 mg/day, P=0.015). Therefore, according to the results, CYP3A4 gene polymorphism has an important effect on the dose of rivaroxaban required to maintain the International Normalized Ratio (INR) in the range of 2-3.
Blood Clots
Cardiovascular Disease
CYP3A4 gene
Genetic Characteristics
Multiple Alleles
https://www.cmbr-journal.com/article_138880.html
2022-03-30T00:32:13+04:30
Microsoft® Word 2010
Muhammed Furkan Ercisli1; Gao Lechun2; Sarhang Hasan Azeez 3; Rebwar Muhammad Hamasalih4; Siyan Song5; Zahra Aziziaram6*
1 Department of Gynecology and Obstetrics, Basaksehir Cam and Sakura City Hospital, University of Health Science, Istanbul, Turkey
2022-03-30T00:33:20+04:30
Microsoft® Word 2010
Blood Clots, Cardiovascular Disease, CYP3A4 gene, Genetic Characteristics, Multiple Alleles
uuid:6b0010cd-74da-4184-b131-04ee33ea88f0
uuid:875c7efc-fc6d-4a49-8370-0e8e33f6ad32
https://www.cmbr-journal.com/article_138880.html
endstream
endobj
30 0 obj
<<
/Filter [/FlateDecode]
/Length 8094
>>
stream
x=ksGrU_u˝Ύs$d%gl:&AH %TSy *+S